Statistiche di base
| CIK | 1619856 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Caribou Biosciences, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 12, 2025 |
Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 - - $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 - BERKELEY, Calif., August 12, 2025 (GLOBE NEWSWIRE) - Caribou Bi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
CARIBOU BIOSCIENCES, INC. 2929 7th Street Suite 105 Berkeley, California 94710 (510) 982-6030 CARIBOU BIOSCIENCES, INC. 2929 7th Street Suite 105 Berkeley, California 94710 (510) 982-6030 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Tim Buchmiller Re: Caribou Biosciences, Inc. (the “Registrant”) - Request for Acceleration Registration Statement on Form S-3 File No. 333-287093 Ladie |
|
| May 8, 2025 |
Exhibit 99.1 Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 - - $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 - BERKELEY, Calif., May 8, 2025 (GLOBE NEWSWIRE) - Caribou Biosc |
|
| May 8, 2025 |
Exhibit 10.2 ADVISORY CONSULTING AGREEMENT This Advisory Consulting Agreement (this “Agreement”) has an effective date of July 1, 2025 (the “Effective Date”), and is by and between Caribou Biosciences, Inc., having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (“Caribou”), and Steven B. Kanner, Ph.D., (“Consultant”) (each herein referred to individually as a “Party” and, collectivel |
|
| May 8, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Caribou Biosciences, Inc. |
|
| May 8, 2025 |
Form of Indenture for Senior Debt Securities EX-4.4 Exhibit 4.4 CARIBOU BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Serie |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| May 8, 2025 |
Form of Indenture for Subordinated Debt Securities Exhibit 4.5 CARIBOU BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Series 5 Sec |
|
| April 25, 2025 |
Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 24, 2025 |
Exhibit 99.1 Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs - Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 - - Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 - - CB-010 ANTLER 2L LBCL Phase 1 da |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2025 |
, from the Registrant to Steven B. Kanner, Ph.D. Exhibit 10.43 February 17, 2025 Steven B. Kanner, Ph.D. Dear Steve: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2024. You will receive a one-time payment of $169,769.00, less applicable withholding taxes, on March 7, 2025. Additionally, your base salary has been increased to $502,030.00, effective January 1, 2025. Your Fe |
|
| March 10, 2025 |
Power of Attorney (reference is made to the signature page hereto). S-8 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Caribou Biosciences, Inc. |
|
| March 10, 2025 |
Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 - - Advancing four clinical programs for hematologic malignancies and autoimmune diseases - - $249.4 million in cash, cash equivalents, and marketable securities expected to fund the |
|
| March 10, 2025 |
Offer Letter between the Registrant and Sriram Ryali, dated December 9, 2024 Exhibit 10.50 Confidential December 9, 2024 Sriram Ryali, M.B.A. XXXXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXXXX RE: Offer Letter of Employment with Caribou Biosciences, Inc. Dear Sri: On behalf of Caribou Biosciences, Inc. (the “Company” or “Caribou”), I am pleased to invite you to join the Company as the Chief Financial Officer, reporting to Rachel E. Haurwitz, Ph.D., President and CEO. The first day |
|
| March 10, 2025 |
, by and between the Registrant and Memorial Sloan Kettering Cancer Center Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 10, 2025 |
Exhibit 19.1 CARIBOU BIOSCIENCES, INC. Amended and Restated Policy on Insider Trading This Amended and Restated Insider Trading Policy (this “Policy”) describes the standards of Caribou Biosciences, Inc. and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in possession of confidential i |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| March 10, 2025 |
for the fiscal year ended December 31, 2024 (File No. 001-40631) Exhibit 10.51 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (“Agreement”) is dated as of January 2, 2025 (“Effective Date”), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the “Company”), and Sriram Ryali (the “Officer”). WHEREAS, the Company desires to employ the Officer and the Officer |
|
| March 10, 2025 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 10, 2025 |
, from the Registrant to Barbara G. McClung, J.D. Exhibit 10.38 February 17, 2025 Barbara G. McClung, J.D. Dear Barbara: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2024. You will receive a one-time payment of $169,769.00, less applicable withholding taxes, on March 7, 2025. Additionally, your base salary has been increased to $502,030.00, effective January 1, 2025. Your |
|
| March 10, 2025 |
, from the Registrant to Rachel E. Haurwitz, Ph.D. Exhibit 10.34 February 17, 2025 Rachel E. Haurwitz, Ph.D. Dear Rachel: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2024. You will receive a one-time payment of $310,387.00, less applicable withholding taxes, on March 7, 2025. Additionally, your base salary has been increased to $667,534.00, effective January 1, 2025. Your |
|
| March 10, 2025 |
Compensation Letter, dated February 17, 2025, from the Registrant to Tim Kelly Exhibit 10.47 February 17, 2025 Timothy Kelly Dear Tim: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2024. You will receive a one-time payment of $166,250.00, less applicable withholding taxes, on March 7, 2025. Additionally, your base salary has been increased to $491,625.00, effective January 1, 2025. Your February 28, 2 |
|
| March 10, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Caribou Biosciences, Inc. Entity State or Jurisdiction of Incorporation or Organization Antler Holdco, LLC Delaware Arboreal Holdco, LLC Delaware Biloba Holdco, LLC Delaware Microbe Holdco, LLC Delaware |
|
| January 13, 2025 |
Exhibit 99.1 Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 - CB-010 GALLOP Phase 1 trial initiated in lupus - - CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 - - CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 2, 2025 |
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer Exhibit 99.1 Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer BERKELEY, Calif., January 2, 2025 (GLOBE NEWSWIRE) - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial expe |
|
| December 6, 2024 |
CRBU / Caribou Biosciences, Inc. / Haurwitz Rachel E. - SC 13D/A Activist Investment SC 13D/A 1 d822535dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 CARIBOU BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 142038 108 (CUSIP Number) Rachel E. Haurwitz c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 1 |
|
| November 14, 2024 |
CRBU / Caribou Biosciences, Inc. / Point72 Asset Management, L.P. Passive Investment SC 13G/A 1 p24-3175sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Caribou Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 14, 2024 |
CRBU / Caribou Biosciences, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1153003913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Caribou Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 14, 2024 |
CRBU / Caribou Biosciences, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Caribou Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 142038108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 14, 2024 |
CRBU / Caribou Biosciences, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427962d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 4)* Caribou Biosciences, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 142038108 (CUSIP Number) |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| November 6, 2024 |
Exhibit 10.1 Confidential May 30, 2024 Tina Albertson, MD, PhD XXXXXXXXX XXXXXXXXX XXXXXXXXX RE: Offer Letter of Employment with Caribou Biosciences, Inc. Dear Tina: On behalf of Caribou Biosciences, Inc. (the “Company” or “Caribou”), I am pleased to invite you to join the Company as a Chief Medical Officer, reporting to Rachel Haurwitz, PhD. The first day of your employment will be August 12, 202 |
|
| November 6, 2024 |
Exhibit 99.1 Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 - - Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data rep |
|
| November 6, 2024 |
Officer Employment Agreement by and between the Registrant and Exhibit 10.2 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (“Agreement”) is dated as of August 12, 2024 (“Effective Date”), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the “Company”), and Tina Albertson, MD, PhD (the “Officer”). WHEREAS, the Company desires to employ the Officer and t |
|
| October 17, 2024 |
CRBU / Caribou Biosciences, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 CaribouBiosciencesInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CARIBOU BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 142038108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2024 |
Exhibit 99.1 Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer -Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies - BERKELEY, Calif., August 12, 2024 (GLOBE NEWSWIRE) - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO OFFICER EMPLOYMENT AGREEMENT This Amendment No. 1 (this “Amendment”), having an effective date of May 29, 2024 (the “Amendment Effective Date”), is made to the Officer Employment Agreement (the “Agreement”), dated July 27, 2021, by and between Caribou Biosciences, Inc., having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (“Caribou”), and Steven B. Ka |
|
| August 6, 2024 |
Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 - - Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 3, 2024 |
Exhibit 99.1 Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies - - 14.4 months median PFS in ANTLER p |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 3, 2024 |
cariboubiosciencesireven CB-010 ANTLER Phase 1 trial update and KOL discussion Transformative genome-edited therapies for patients June 2, 2024 2 KOL discussion CB-010 ANTLER Phase 1 data | June 2024 ©2024 Caribou Biosciences, Inc. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| May 7, 2024 |
Exhibit 99.1 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update - Advancing CB-010 ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - - Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 c |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 25, 2024 |
Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| April 4, 2024 |
Caribou Biosciences Expands Clinical Development of CB- 010 with FDA Clearance of IND in Lupus April 4, 2024 2 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. |
|
| April 4, 2024 |
Exhibit 99.1 Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus - FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 - - Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expand |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 04, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 11, 2024 |
Exhibit 97.1 CARIBOU BIOSCIENCES, INC. CLAWBACK POLICY Purpose Caribou Biosciences, Inc. (“Company”) is establishing this policy to align the interests of executive officers of the Company with those of shareholders and to create and maintain a culture that emphasizes integrity and accountability. This policy provides for the recoupment of certain executive compensation in the event of an accounti |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 11, 2024 S-8 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. |
|
| March 11, 2024 |
Compensation Letter, dated February 20, 2024, from the Registrant to Exhibit 10.49 February 20, 2024 Ruhi Khan Dear Ruhi: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2023. You will receive a one-time payment of $168,920, less applicable withholding taxes, on March 8, 2024. Additionally, your base salary has been increased to $443,415, effective January 1, 2024. Your February 29, 2024 paych |
|
| March 11, 2024 |
Officer Employment Agreement by and between the Registrant and Exhibit 10.55 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (“Agreement”) is dated as of January 1, 2024 (“Effective Date”), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the “Company”), and Tim Kelly (the “Officer”). WHEREAS, the Company desires to employ the Officer and the Officer de |
|
| March 11, 2024 |
Exhibit 10.54 Confidential November 22, 2023 Tim Kelly RE: Offer Letter of Employment with Caribou Biosciences, Inc. Dear Tim: On behalf of Caribou Biosciences, Inc. (the “Company” or “Caribou”), I am pleased to invite you to join the Company as the Chief Technology Officer, reporting to Rachel Haurwitz, Ph.D. The first day of your employment will be January 1, 2024, or such other date as you and |
|
| March 11, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Caribou Biosciences, Inc. Entity State or Jurisdiction of Incorporation or Organization Antler Holdco, LLC Delaware Arboreal Holdco, LLC Delaware Biloba Holdco, LLC Delaware Microbe Holdco, LLC Delaware |
|
| March 11, 2024 |
Compensation Letter, dated February 20, 2024, from the Registrant to Rachel E. Haurwitz, Ph.D. Exhibit 10.32 February 20, 2024 Rachel E. Haurwitz, Ph.D. Dear Rachel: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2023. You will receive a one-time payment of $342,733, less applicable withholding taxes, on March 8, 2024. Additionally, your base salary has been increased to $644,960, effective January 1, 2024. Your Febru |
|
| March 11, 2024 |
Compensation Letter, dated February 20, 2024, from the Registrant to Exhibit 10.41 February 20, 2024 Barbara G. McClung, JD Dear Barbara: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2023. You will receive a one-time payment of $187,460, less applicable withholding taxes, on March 8, 2024. Additionally, your base salary has been increased to $485,053, effective January 1, 2024. Your Februar |
|
| March 11, 2024 |
Separation Letter, dated December 19, 2023, between the Registrant and Syed Rizvi, M.D. Exhibit 10.53 December 19, 2023 Syed Rizvi, M.D. XXXXXXXXX XXXXXXXXX XXXXXXXXX Dear Syed: This letter (the “Agreement”) confirms the agreement between you and Caribou Biosciences, Inc. (the “Company”) regarding the termination of your employment with the Company. 1.Separation Date. Your employment with the Company will end effective at 5 p.m. Pacific time on December 31, 2023 (the “Separation Date |
|
| March 11, 2024 |
Compensation Letter, dated February 20, 2024, from the Registrant to Exhibit 10.37 February 20, 2024 Jason V. O’Byrne Dear Jason: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2023. You will receive a one-time payment of $181,280, less applicable withholding taxes, on March 8, 2024. Additionally, your base salary has been increased to $469,062, effective January 1, 2024. Your February 29, 20 |
|
| March 11, 2024 |
Compensation Letter, dated February 20, 2024, from the Registrant to Exhibit 10.45 February 20, 2024 Steven B. Kanner, Ph.D. Dear Steve: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2023. You will receive a one-time payment of $187,460, less applicable withholding taxes, on March 8, 2024. Additionally, your base salary has been increased to $485,053, effective January 1, 2024. Your February |
|
| March 11, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Caribou Biosciences, Inc. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| March 11, 2024 |
Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 - - 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML - - $372.4 million in cash, cash equivalents, and marketable secur |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 23, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-1020exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| February 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caribou Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) February 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2024 |
CRBU / Caribou Biosciences, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm245198d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Caribou Biosciences, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 142038108 (CUSIP Number) D |
|
| February 14, 2024 |
SC 13G/A 1 p24-0504sc13ga.htm CARIBOU BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Caribou Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| January 8, 2024 |
Exhibit 99.1 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - Tim Kelly to lead Caribou’s technical operations strategy and execution - - CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 - - CB-011 CaMMouflage |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 8, 2024 |
CRBU / Caribou Biosciences, Inc. / Avidity Partners Management LP Passive Investment SC 13G 1 d1092786713-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Caribou Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 12, 2023 |
Exhibit 99.1 Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 - Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT - - ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expec |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| November 7, 2023 |
Exhibit 99.1 Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update - CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 - - CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients - - CB-012 AMpLify Phase |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 18, 2023 |
Exhibit 99.1 Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia - AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 - - CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic |
|
| October 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 26, 2023 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 8, 2023 |
Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update - CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 - - CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM - - CB-012 IND application submission for r/r AML planned for |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| July 20, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caribou Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) July 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| July 20, 2023 |
Youâve Exceeded the SECâs Traffic Limit EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| July 17, 2023 |
Exhibit 1.1 EXECUTION VERSION CARIBOU BIOSCIENCES, INC. (a Delaware corporation) 19,230,769 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 13, 2023 CARIBOU BIOSCIENCES, INC. (a Delaware corporation) 19,230,769 Shares of Common Stock UNDERWRITING AGREEMENT July 13, 2023 BofA Securities, Inc. SVB Securities LLC Evercore Group L.L.C. as Representatives of the several Underwriters c/o BofA |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 17, 2023 |
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering Exhibit 99.2 Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering BERKELEY, CA, July 13, 2023 (GLOBE NEWSWIRE) – Caribou Biosciences, Inc. (Nasdaq: CRBU) (https://www.cariboubio.com/), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a |
|
| July 17, 2023 |
Caribou Biosciences Announces Proposed Public Offering of Common Stock Exhibit 99.1 Caribou Biosciences Announces Proposed Public Offering of Common Stock BERKELEY, CA, July 13, 2023 (GLOBE NEWSWIRE) – Caribou Biosciences, Inc. (Nasdaq: CRBU) (https://www.cariboubio.com/), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou int |
|
| July 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Caribou Biosciences, Inc. |
|
| July 14, 2023 |
19,230,769 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266712 PROSPECTUS SUPPLEMENT (To the prospectus dated August 16, 2022) 19,230,769 Shares of Common Stock We are offering 19,230,769 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “CRBU.” On July 13, 2023, the last reported sale price of our common stock on The N |
|
| July 14, 2023 |
cariboubiosciencesantler ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023 2 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. |
|
| July 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 13, 2023 |
Exhibit 99.1 Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL - CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies - - 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 13, 2023 |
cariboubiosciencesantler ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023 2 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. |
|
| July 13, 2023 |
Subject to Completion, dated July 13, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266712 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these secu |
|
| July 13, 2023 |
cariboubioscienceswebcas CB-010 clinical program update Transformative genome-edited therapies for patients July 13, 2023 2 CB-010 clinical program update | July 2023 ©2023 Caribou Biosciences, Inc. |
|
| July 10, 2023 |
CRBU / Caribou Biosciences Inc / PFIZER INC - SC 13G CARIBOU BIOSCIENCES Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CARIBOU BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| July 6, 2023 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 29, 2023, between Caribou Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the “Purchaser”). WHEREAS, the Company and the Purchaser |
|
| July 6, 2023 |
Exhibit 99.1 Caribou Biosciences Announces $25 Million Equity Investment from Pfizer - Pfizer purchases $25 million of Caribou common shares - - Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development has joined Caribou’s Scientific Advisory Board - BERKELEY, CA, July 6, 2023 – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-s |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 6, 2023 |
filed by the Registrant with the SEC on Exhibit 10.2 Execution Version VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of June 29, 2023, is made by and between Caribou Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (“Pfizer”). Each of the Company and Pfizer may be referred to herein as |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
Exhibit 99.1 Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update - CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 - - CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 - - CB-012 IND application for r/r AML planned for H2 2023 - - $291.0 million in c |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| April 28, 2023 |
DEFA14A 1 cariboubiosciencesincvx.htm DEFA14A Your Vote Counts! CARIBOU BIOSCIENCES, INC. 2929 7TH STREET SUITE 105 BERKELEY, CA 94710 CARIBOU BIOSCIENCES, INC. 2023 Annual Meeting Vote by June 14, 2023 11:59 PM EDT You invested in CARIBOU BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding th |
|
| April 28, 2023 |
crbu-20221231x10xk UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 4, 2023 |
Exhibit 99.1 Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma - CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 - BERKELEY, CA, April 4, 2023– Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t |
|
| March 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 29, 2023 |
Exhibit 99.1 Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma - CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection - - CB-011 is Caribou’s second program to enter the clinic from |
|
| March 29, 2023 |
Exhibit 99.1 Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients - CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients - - Next ANTLER update planned for H2 2023 - BERKELEY, CA, March 29, 2023 – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stag |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Syed Rizvi, M.D. Exhibit 10.50 February 16, 2023 Syed Rizvi, M.D. c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Syed, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $172,359.18, less applicable withholding taxes, on March 3, 2023. Additionally, your base |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| March 9, 2023 |
Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 - - CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 - - CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 - - $317.0 million in c |
|
| March 9, 2023 |
Compensation Letter, dated February 11, 2022, from the Registrant to Ruhi Khan Exhibit 10.46 February 11, 2022 Ruhi Khan XXXXXXXXX XXXXXXXXX Dear Ruhi: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company’s achievements in 2021. You will receive a one-time payment of $26,650, less applicable withholding taxes, on February 22, 2022. Congratulations! Your base salary is $410,000 and your target bonus will be 40% in 2022 for you |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Rachel E. Haurwitz, Ph.D. Exhibit 10.34 February 16, 2023 Rachel Haurwitz, Ph.D. c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Rachel, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $307,793.75, less applicable withholding taxes, on March 3, 2023. Additionally, yo |
|
| March 9, 2023 |
, 2023, between the Registrant and AbbVie Manufacturing Management Unlimited Company Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Barbara G. McClung, J.D. Exhibit 10.41 February 16, 2023 Barbara McClung, J.D. c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Barbara, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $168,350.00, less applicable withholding taxes, on March 3, 2023. Additionally, yo |
|
| March 9, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Caribou Biosciences, Inc. Entity State or Jurisdiction of Incorporation or Organization Antler Holdco, LLC Delaware Arboreal Holdco, LLC Delaware Biloba Holdco, LLC Delaware Microbe Holdco, LLC Delaware |
|
| March 9, 2023 |
Power of Attorney (reference is made to the signature page hereto). S-8 1 d467633ds8.htm S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Caribou Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-3728228 (State or other jurisdiction of incorporation |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Jason V. O’Byrne Exhibit 10.38 February 16, 2023 Jason O’Byrne c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Jason, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $162,800.00, less applicable withholding taxes, on March 3, 2023. Additionally, your base sa |
|
| March 9, 2023 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Steven B. Kanner, Ph.D. Exhibit 10.44 February 16, 2023 Steven Kanner, Ph.D. c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Steve, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $168,350.00, less applicable withholding taxes, on March 3, 2023. Additionally, your |
|
| March 9, 2023 |
Compensation Letter, dated February 16, 2023, from the Registrant to Ruhi Khan Exhibit 10.47 February 16, 2023 Ruhi Khan c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Dear Ruhi, I am pleased to announce that the Caribou Board of Directors has approved a bonus for you based on the Company’s achievements in 2022. You will receive a one-time payment of $151,700.00, less applicable withholding taxes, on March 3, 2023. Additionally, your base salary |
|
| March 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Caribou Biosciences, Inc. |
|
| February 14, 2023 |
CRBU / Caribou Biosciences, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d3sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Caribou Biosciences, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 142038108 (CUSIP Number) De |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 12, 2022 |
Exhibit 99.1 Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress - Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r/r B-NHL - - ANTLER trial enrolling patients at dose level 3 - BERKELEY, CA, December 12, 2022 – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today |
|
| December 12, 2022 |
Exhibit 99.2 Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy - Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today - - Caribou is using its chRDNA next-gen CRISPR technology to engineer and advance both CAR-NK and CAR-T cell therapy programs - B |
|
| November 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 29, 2022 |
Exhibit 99.1 Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy - RMAT and Fast Track designations follow CB-010?s durable complete responses at dose level 1 in the ANTLER Phase 1 trial - - CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout - BE |
|
| November 21, 2022 |
Exhibit 99.1 Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma - CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 - - CB-011 is engineered with a differentiated immune cloaking strategy, designed to enhance persistence - - C |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| November 8, 2022 |
Exhibit 10.2 CARIBOU BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE Caribou Biosciences, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of performance stock units (?Performance Stock Units? or ?PSUs?). Each vested Performance Stock |
|
| November 8, 2022 |
Exhibit 10.1 CARIBOU BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Caribou Biosciences, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSUs?). Each vested Restricted Stock Unit |
|
| November 8, 2022 |
Exhibit 99.1 Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update - CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 - - CB-011 IND application for r/r MM submitted to FDA in Q4 2022 - - Strong financial position of $342.6 million in cash, cash equivalents, and marketable securities as of September 30, 20 |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 3, 2022 |
Exhibit 99.1 Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting BERKELEY, CA, November 3, 2022 – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that a trial-in-progress abstract for the Company’s ongoing ANTLER Phase 1 clinical trial evaluating |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 18, 2022 |
Exhibit 99.1 Exhibit 99.1 Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022 - Ongoing complete response at 15 months reported in first patient treated with CB-010 - BERKELEY, CA, October 18, 2022 ? Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing b |
|
| October 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 23, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of I |
|
| September 22, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 12, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2022 |
CARIBOU BIOSCIENCES, INC. 2929 7th Street Suite 105 Berkeley, California 94710 (510) 982-6030 CORRESP 1 filename1.htm CARIBOU BIOSCIENCES, INC. 2929 7th Street Suite 105 Berkeley, California 94710 (510) 982-6030 August 12, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.C. 20549 Attention: Margaret Schwartz Re: Caribou Biosciences, Inc. (the “Registrant”) - Request for Acceleration Registration Statement on Form S |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 11, 2022 |
DEF 14A 1 crbuproxy2022annualm.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 9, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 9, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Caribou Biosciences, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common |
|
| August 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Caribou Biosciences, Inc. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| August 9, 2022 |
EX-99.1 2 crbu-ex991.htm EX-99.1 Exhibit 99.1 Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update - 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial - - Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial - - CB-011 IND submission planned for Q4 2022 in patients |
|
| August 9, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on August 9, 2022 Registration No. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2022 |
Form of Indenture for Senior Debt Securities Exhibit 4.4 CARIBOU BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Series 5 Sect |
|
| August 9, 2022 |
Form of Indenture for Subordinated Debt Securities Exhibit 4.5 CARIBOU BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Series 5 Sec |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 10, 2022 |
Transformative genome-edited therapies for patients ANTLER initial clinical data for CB-010 at EHA 2022 June 10, 2022 Exhibit 99. |
|
| June 10, 2022 |
Exhibit 99.1 Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress - 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL - - First patien |
|
| June 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 1, 2022 |
CRBU / Caribou Biosciences, Inc. / DUPONT E I DE NEMOURS & CO - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment NO. 1)* Caribou BioSciences, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 4203810 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| June 1, 2022 |
EXHIBIT 99.1 Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022 - Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients - BERKELEY, CA, June 1, 2022 ? Caribou Biosciences, Inc. (Nasdaq: CRBU), a lead |
|
| June 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
Exhibit 99.1 Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy - 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL - - CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) - - Based on promising initial safety profile, |
|
| May 12, 2022 |
Transformative genome-edited therapies for patients CB-010 Clinical Program Update May 12, 2022 Transformative genome-edited therapies for patients CB-010 Clinical Program Update May 12, 2022 Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 11, 2022 |
Exhibit 99.1 Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors - Mr. Johnson brings 30 years of commercial experience to Caribou as company’s pipeline of genome-edited cell therapies advances - BERKELEY, CA, May 11, 2022 (GLOBE NEWSWIRE) – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today ann |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 99.1 Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates - Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy candidate, in patients with r/r B-NHL - - Submission of IND application planned in H2 2022 for CB-011, Caribo |
|
| April 25, 2022 |
Exhibit 99.1 Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress -Abstract accepted for initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou?s lead allogeneic cell therapy for patients with r/r B-NHL - BERKELEY, CA, April 25, 2022 (GLOBE NEWSWIRE) ? Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading |
|
| April 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 21, 2022 |
Offer Letter, dated October 29, 2021, between the Registrant and Syed Rizvi Exhibit 10.41 Confidential October 29, 2021 Syed Rizvi, M.D. XXXXXXXXX XXXXXXXXX XXXXXXXXX RE: Offer of Employment with Caribou Biosciences, Inc. Dear Syed: On behalf of Caribou Biosciences, Inc. (the ?Company? or ?Caribou?), I am pleased to invite you to join the Company as Chief Medical Officer, reporting to Rachel E. Haurwitz, President and Chief Executive Officer. The first day of your employm |
|
| March 21, 2022 |
Exhibit 10.50 Employee Form CARIBOU BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2021 Equity Incentive Plan (the ?Plan?) shall have the same defined meanings in this Stock Option Agreement (the ?Option Agreement?). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned (the ?Participant?) has been granted an O |
|
| March 21, 2022 |
Offer Letter between the Registrant and Jason V. O'Byrne Exhibit 10.33 Confidential January 5, 2021 Jason O?Byrne XXXXXXXXX XXXXXXXXX XXXXXXXXX RE: Offer of Employment with Caribou Biosciences, Inc. Dear Jason: On behalf of Caribou Biosciences, Inc. (the ?Company? or ?Caribou?), I am pleased to invite you to join the Company as Chief Financial Officer, reporting to Rachel E. Haurwitz, President and Chief Executive Officer. The first day of your employme |
|
| March 21, 2022 |
Exhibit 4.1 CARIBOU BIOSCIENCES, INC. DESCRIPTION OF COMMON STOCK Caribou Biosciences, Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) ? common stock, par value $0.0001 per share (the ?Common Stock?). The Common Stock trades on The Nasdaq Global Select Market under the trading symbol ?CRBU.? The fo |
|
| March 21, 2022 |
Compensation Letter, dated February 11, 2022, from the Registrant to Ruhi Khan Exhibit 10.40 February 11, 2022 Ruhi Khan 311 Cervantes Road Portola Valley, CA 94028 Dear Ruhi: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company?s achievements in 2021. You will receive a one-time payment of $26,650, less applicable withholding taxes, on February 22, 2022. Congratulations! Your base salary is $410,000 and your target bonus wil |
|
| March 21, 2022 |
Compensation Letter, dated February 11, 2022, from the Registrant to Barbara G. McClung, J.D. Exhibit 10.36 February 11, 2022 Barbara McClung XXXXXXXXX XXXXXXXXX Dear Barbara: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company?s achievements in 2021. You will receive a one-time payment of $182,350 less applicable withholding taxes, on February 22, 2022. Congratulations! Additionally, your base salary has been increased to $455,000, effect |
|
| March 21, 2022 |
Exhibit 10.27 FIRST AMENDMENT (2929 Seventh Street, Berkeley, California) This First Amendment (this ?Amendment?), dated as of January II, 2022, is entered into by and between 2929 SEVENTH ST., LLC, a California limited liability company (?Landlord?), and CARIBOU BIOSCIENCES, INC., a Delaware corporation (?Tenant?). Recitals A. Landlord and Tenant entered into that certain Amended and Restated Off |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 21, 2022 |
Exhibit 10.52 CARIBOU BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Caribou Biosciences, Inc., a Delaware corporation (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSUs?). Each vested Restricted Stock Unit |
|
| March 21, 2022 |
Exhibit 10.39 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (?Agreement?) is dated as of November 8, 2021 (?Effective Date?), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the ?Company?), and Ruhi Khan, M.B.A. (the ?Officer?). WHEREAS, the Company desires to employ the Officer and the O |
|
| March 21, 2022 |
Compensation Letter, dated February 11, 2022, from the Registrant to Rachel E. Haurwitz, Ph.D. Exhibit 10.31 February 11, 2022 Rachel E Haurwitz XXXXXXXXX XXXXXXXXX Dear Rachel: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company?s achievements in 2021. You will receive a one-time payment of $319,069, less applicable withholding taxes, on February 22, 2022. Congratulations! Additionally, your base salary has been increased to $605,000, effe |
|
| March 21, 2022 |
Exhibit 10.51 Non-employee Director Form CARIBOU BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2021 Equity Incentive Plan (the ?Plan?) shall have the same defined meanings in this Stock Option Agreement (the ?Option Agreement?). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned (the ?Participant?) has been |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| March 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Caribou Biosciences, Inc. |
|
| March 21, 2022 |
Exhibits 10.29 RIDER 1 COMMENCEMENT DATE AGREEMENT Wareham-NZL, LLC, a California limited liability company (?Landlord?), and Caribou Biosciences, a Delaware Corporation (?Tenant?), have entered into a certain Office/Laboratory Lease dated as of January 11, 2022 (the ?Lease?). WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date of the Lease as provided for in Section |
|
| March 21, 2022 |
Exhibit 10.46 AMENDMENT TO CARIBOU BIOSCIENCES, INC. 2013 EQUITY INCENTIVE PLAN Effective December 9, 2021, the following paragraphs of the Caribou Biosciences, Inc. 2013 Equity Incentive Plan, as amended and restated as of April 3, 2019, (the ?Plan?) are amended to read as follows, with amendments marked as indicated: 13. Limited Transferability of Shares Underlying Awards (a) General. Notwithsta |
|
| March 21, 2022 |
List of Subsidiaries of the Registrant EX-21.1 18 crbu-ex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Caribou Biosciences, Inc. Entity State or Jurisdiction of Incorporation or Organization Antler Holdco, LLC Delaware Arboreal Holdco, LLC Delaware Biloba Holdco, LLC Delaware Microbe Holdco, LLC Delaware |
|
| March 21, 2022 |
Compensation Letter, dated February 11, 2022, from the Registrant to Steven B. Kanner, Ph.D. Exhibit 10.38 February 11, 2022 Steve Kanner XXXXXXXXX XXXXXXXXX Dear Steve: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company?s achievements in 2021. You will receive a one-time payment of $181,100, less applicable withholding taxes, on February 22, 2022. Congratulations! Additionally, your base salary has been increased to $455,000, effective |
|
| March 21, 2022 |
Compensation Letter, dated February 11, 2022, from the Registrant to Jason V. O’Byrne Exhibit 10.34 February 11, 2022 Jason O'Byrne XXXXXXXXX XXXXXXXXX Dear Jason: I am pleased to announce that the Caribou Board of Directors has approved a bonus based on the Company?s achievements in 2021. You will receive a one-time payment of $157,775, less applicable withholding taxes, on February 22, 2022. Congratulations! Additionally, your base salary has been increased to $440,000, effective |
|
| March 21, 2022 |
Exhibit 10.42 OFFICER EMPLOYMENT AGREEMENT This Officer Employment Agreement (?Agreement?) is dated as of January 18, 2022 (?Effective Date?), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the ?Company?), and Syed Rizvi, M.D. (the ?Officer?). WHEREAS, the Company desires to employ the Officer and the Of |
|
| March 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 21, 2022 |
Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL - - 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for p |
|
| March 1, 2022 |
CRBU / Caribou Biosciences, Inc. / DUPONT E I DE NEMOURS & CO - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Caribou BioSciences, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 4203810 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
EX-99.1 2 tm225765d1ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Caribou Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Ex |
|
| February 14, 2022 |
CRBU / Caribou Biosciences, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Caribou Biosciences, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 142038108 (CUSIP Number) December 31, 2021 (Date of Event Which Re |
|
| February 11, 2022 |
CRBU / Caribou Biosciences, Inc. / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT #1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2022 |
CRBU / Caribou Biosciences, Inc. / Haurwitz Rachel E. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. )* Under the Securities Exchange Act of 1934 CARIBOU BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 142038 108 (CUSIP Number) Rachel E. Haurwitz c/o Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, California 94710 (510) 982- |
|
| January 19, 2022 |
EX-10.1 2 crbu-ex101.htm EX-10.1 Exhibit 10.1 OFFICE/LABORATORY LEASE BETWEEN 7TH STREET PROPERTY III GENERAL PARTNERSHIP (LANDLORD) AND CARIBOU BIOSCIENCES, INC. (TENANT) 2895 Seventh Street Berkeley, California 00066513.5 Table of Contents Page ARTICLE 1 BASIC LEASE PROVISIONS 1 1.1 BASIC LEASE PROVISIONS 1 1.2 ENUMERATION OF EXHIBITS AND RIDER(S) 3 1.3 DEFINITIONS 3 ARTICLE 2 PREMISES, TERM, FA |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 18, 2022 |
EX-99.1 2 crbu-ex991.htm EX-99.1 EXHIBIT 99.1 Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer Dr. Rizvi brings significant experience in oncology cell therapy development BERKELEY, CA, January 18, 2022 (GLOBE NEWSWIRE) – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed |
|
| November 9, 2021 |
EX-10.1 2 crbu-ex101.htm EX-10.1 Exhibit 10.1 Exhibit 10.1 CARIBOU BIOSCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Amended and Restated 2013 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). For the avoidance of doubt, thi |
|
| November 9, 2021 |
EX-99.1 2 crbu-ex991.htm EX-99.1 Exhibit 99.1 Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and Dara Richardson-Heron, M.D., to board of directors and Ruhi Khan as chief busi |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 Caribou Biosciences, Inc. |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2021 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2021 |
Exhibit 99.1 Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer BERKELEY, CA, November 8, 2021 (GLOBE NEWSWIRE) ? Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointments of Dara Richardson-Heron, M.D., to its board of directors and Ru |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2021 Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40631 45-3728228 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 29, 2021 |
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors Exhibit 99.1 Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors BERKELEY, CA ? September 29, 2021? Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership exp |
